Physiologically, LQTS-associated CaM mutations that have been probed for effects on Cav1.2 regulation have demonstrated a reduction in CDI to varying extents [15,65,67,69,70,77,87,90,91,119]. This evidence concerns the gene CACNA1C and familial long QT syndrome.